Clinical Trial Update: A Dose-Finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects With Refractory Asthma [Phase 2]

View source ↗

Summary

A Phase 2 dose-finding trial of adalimumab in subjects with refractory asthma was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: Abbott | Conditions: Asthma | Phase 2 | Status: WITHDRAWN